94
Participants
Start Date
August 20, 2021
Primary Completion Date
February 1, 2024
Study Completion Date
February 1, 2024
Ociperlimab
900 mg intravenously once every 3 weeks (dosed in 21-day cycles)
Tislelizumab
200 mg intravenously once every 3 weeks (dosed in 21-day cycles)
BAT1706
15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)
National Cheng Kung University Hospital, Tainan City
Chi Mei Medical Center, Tainan City
Taipei Veterans General Hospital, Taipei
Linkou Chang Gung Memorial Hospital, Taoyuan District
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Beijing Cancer Hospital, Beijing
National Taiwan University Hospital, Taipei
The First Hospital of China Medical University, Shenyang
Shengjing Hospital of China Medical University, Shenyang
Harbin Medical University Cancer Hospital, Harbin
Affiliated Zhongshan Hospital of Fudan University, Shanghai
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Tianjin Third Central Hospital, Tianjin
Zhejiang University College of Medicine Second Affiliated Hospital, Hangzhou
Zhejiang Provincial Peoples Hospital, Hangzhou
Huzhou Central Hospital, Huzhou
Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital), Ningbo
Jinhua Municipal Central Hospital, Jinhua
The Second Affiliated Hospital of Nanchang University, Nanchang
Fujian Cancer Hospital, Fuzhou
Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou
Chongqing Three Gorges Central Hospital, Chongqing
Hunan Cancer Hospital, Changsha
Hubei Cancer Hospital, Wuhan
The First Affiliated Hospital, Sun Yat Sen University, Guangzhou
Nanfang Hospital of Southern Medical University, Guangzhou
West China Hospital, Sichuan University, Chengdu
Karamay Central Hospital of Xinjiang, Karamay
Lead Sponsor
BeiGene
INDUSTRY